About Us

Through the participation of innovation around the world, we will continue to provide better innovation results for human health. Establish a diversified product system, and deeply cultivate the three major sectors of finished medicines, APIs, and functional foods; The Group's mRNA vaccine product is the first self-developed and urgently authorized new crown vaccine in China. In the fields of cardiovascular and cerebrovascular, anti-tumor and other fields, innovative drugs such as Enbipu, Mingfule, Duoenyi, Jinlitai, Haiyitan, Duoenda, and Ouyuexin have been marketed. Enbipu, Xuanning and Jinyouli all won the second prize of the National Science and Technology Progress Award, which is the highest national award in the pharmaceutical field. In 2023, two national Category 1 new drugs will be launched: nalusolimab injection (the world's first IgG4 RANKL inhibitor) and glutalitenib tablets (global independent intellectual property rights). The Group also deeply builds the global industrial chain through APIs, which account for an absolute share of the international market, and protects the safety and stability of the international pharmaceutical industry chain.